pharmaceutical investing Johnson & Johnson announces new ICOTYDE® data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy 02 October
pharmaceutical investing New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause 01 October
pharmaceutical investing Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® in generalized myasthenia gravis 29 September
